AAZTA	6-[Bis(carboxymethyl)amino]-1:4-bis(carboxymethyl)-6-methyl-1:4-diazepane
ADC	antibody drug conjugates
ANTA	N,N-Bis(carboxymethyl)-l-lysine
DEDPA	6,6′-((ethane-1,2-diylbis(azanediyl))bis(methylene))dipicolinic acid
DFO	desferrioxamine B
DFT	density functional theory
DOTA	1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
DTPA	2,2′,2′′,2′′′-((((carboxymethyl)azanediyl)bis(ethane-2,1-diyl))bis(azanetriyl))tetraacetic acid
DUPA	2-[3-(1,3-dicarboxypropyl)-ureido]pentane-dioic acid
EDTA	ethylenediaminetetraacetic acid
FDA	US food & drug administration
FR	folate receptor
GEP-NETs	gastroenteropancreatic neuroendocrine tumors
HBED	bis(2-hydroxybenzyl)ethylene-diamine-diacetic acid
HBED-CC	3,3′-(((ethane-1,2-diylbis((carboxymethyl)azanediyl))bis(methylene))bis(4-hydroxy-3,1-phenylene))dipropionic acid
HOPO	hydroxypyridinone
HP	hydroxypyridinone
LET	linear energy transfer
NETs	neuroendocrine tumors
NHL	non-Hodgkin’s lymphoma
NOTA	1,4,7-triazacyclononane-1,4,7-triacetic acid
NOTP	((1,4,7-triazonane-1,4,7-triyl)tris(methylene))tris(phosphonic acid)
NTA	nitrilotriacetic acid
NTP	nitrilo-tripropionic acid
mAbs	monoclonal antibodies
PET	positron emission tomography
PSMA	prostate specific membrane antigen
RBE	relative biological effectiveness
RGD	cyclic RGDfK peptide
SPECT	single photon emission computed tomography
TACD	1,5,9-triazacyclododecane
TACN	1,4,7-triazacyclononane
TAT	targeted alpha therapy
TATE	octreotate
THP	tris(hydroxypyridinone)
THPN	1,3-propanediamine-N,N,N′,N′-tetrakis[(2-(aminomethyl)-3-hydroxy-1,6-dimethyl-4(1H)- pyridinone)acetamide]
TREN	tris(2-aminoethyl)amine
WT	weighting factor